March 23, 2021

Selexis and Tallac Therapeutics Collaborate to Advance Tallac’s Pipeline of Novel Immunotherapies in Oncology

Read More
March 18, 2021

SpyBiotech Licenses Selexis Best-in-Class Cell Line Development Technologies to Advance Human Cytomegalovirus VLP Vaccine Program

Read More
March 16, 2021

Selexis Enters Service Agreement with Pandion Therapeutics to Advance Pandion Antibody

Read More
March 09, 2021

Selexis and Boston Immune Technologies and Therapeutics (BITT) Enter Service Agreement to Advance BITT’s Lead TNFR2 Oncology Candidate

Read More
October 20, 2020

JSR Life Sciences Expands its European Gene-to-GMP Biologics Manufacturing Facilities for Selexis and KBI Biopharma in Geneva, Switzerland

Read More